US clinical-stage biopharmaceutical company Opus Genetics Inc (NASDAQ:IRD) on Wednesday announced a strategic partnership with the Global RDH12 Alliance to accelerate development of OPGx-RDH12, a gene therapy candidate targeting RDH12-associated Leber congenital amaurosis (RDH12-LCA), a rare inherited retinal disease that leads to early childhood vision loss.
The Global RDH12 Alliance comprises non-profit advocacy groups including RDH12 Fund for Sight (US) and Eyes on the Future (UK), both focused on advancing treatment for RDH12-related conditions. Under the agreement, the Alliance will contribute up to USD1.6m toward development efforts.
The partnership features a risk-sharing structure and performance-based milestones, with both parties collaborating on clinical and regulatory strategies. A key objective is to submit an Investigational New Drug (IND) application to the US Food and Drug Administration by late 2025.
RDH12-LCA is an ultra-rare condition affecting a few thousand individuals globally, with symptoms typically manifesting before the age of two. OPGx-RDH12 utilises an adeno-associated virus vector to deliver a functional copy of the RDH12 gene to retinal photoreceptors.
Preclinical studies of OPGx-RDH12 have demonstrated restored RDH12 activity and functional improvements in cell and mouse models.
AN2 Therapeutics and DNDi partner to advance oral therapy for chronic Chagas disease
Opus Genetics partners with Global RDH12 Alliance to advance gene therapy for childhood blindness
Lantern Pharma reports first complete response with LP-284 in heavily pretreated lymphoma patient
DualityBio's HER3 ADC DB-1310 granted US FDA Fast Track Designation
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Orion and Bayer receive EU approval for darolutamide in metastatic hormone-sensitive prostate cancer
Ondine Biomedical completes world-first ICU study with Steriwave nasal therapy
CorestemChemon partners with ATG Lifetech to provide next-gen preclinical services
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
Nicox signs licensing deal with Kowa for NCX 470 rights
Citius Oncology prices USD9.0m public offering
Genetic Leap's GL-IL2-138 receives FDA IND clearance
Amphix Bio's AMFX-200 receives US FDA Orphan Drug Designation to treat acute spinal cord injury